Vor Biopharma director Andrew Levin resigns; David Zaccardelli appointed to board
Vor Biopharma director Andrew Levin resigned from the board effective immediately on July 6, 2026, and the company said the resignation was not due to any disagreement. On July 7, 2026, the board appointed David Zaccardelli, Pharm.D., a former pharmaceutical chief executive, to fill the vacancy as an independent Class II director. The change is a board-level administrative update with no stated effect on operations or financial results.
Key points
- Andrew Levin, M.D., Ph.D. resigned as a director effective immediately; notice delivered July 6, 2026
- David Zaccardelli, Pharm.D., 61, appointed July 7, 2026 as an independent Class II director, serving until the 2029 annual meeting
- Zaccardelli receives a $40,000 annual cash retainer and an initial option grant of up to 68,000 shares or $700,000 in grant-date value, whichever is lower
- He has not yet been named to any board committee
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.